依美昔单抗 (INN :ecromeximab;开发代号:KW2871 )是一种嵌合单克隆抗体 ,正在开发用于治疗恶性黑色素瘤 。[ 1] [ 2] 该药物被用来针对转移性黑色素瘤 进行I期临床试验,[ 3] 并在随后与高剂量的干扰素α2b 联合进行了II期临床试验。[ 4] [ 5]
该药物由协和发酵工业株式会社开发。截至2015年12月,开发已停止。[ 6]
参考资料
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab (页面存档备份 ,存于互联网档案馆 ), American Medical Association .
^ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
^ Forero, Andres; Shah, Jatin; Carlisle, Ronda; Triozzi, Pierre L.; LoBuglio, Albert F.; Wang, Wen-Quan; Fujimori, Matt; Conry, Robert M. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma . Cancer Biotherapy & Radiopharmaceuticals. 2006-12, 21 (6) [2024-03-06 ] . ISSN 1084-9785 . PMID 17257071 . doi:10.1089/cbr.2006.21.561 . (原始内容存档 于2024-06-04).
^ Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma - Full Text View - ClinicalTrials.gov . clinicaltrials.gov. [2024-03-06 ] . (原始内容存档 于2021-04-10) (英语) .
^ Tarhini, Ahmad A.; Moschos, Stergios J.; Lin, Yan; Lin, Hui-Min; Sander, Cindy; Yin, Yan; Venhaus, Ralph; Gajewski, Thomas F.; Kirkwood, John M. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma . Melanoma Research. 2017-08, 27 (4) [2024-03-06 ] . ISSN 1473-5636 . PMID 28489678 . doi:10.1097/CMR.0000000000000353 . (原始内容存档 于2024-06-03).
^ Adis insight: Ecromeximab . [2024-03-06 ] . (原始内容存档 于2017-01-03).